Skip to main content

Table 2 Weight Change with Doxazosin

From: A Review of the Adverse Effects of Peripheral Alpha-1 Antagonists in Hypertension Therapy

Study

Number of

subjects

Type of

Study

Weight change in kilograms

(number on therapy)

   

Doxazosin

Placebo

Other therapy

p-value

Ames [30]

147

RCT

+1.5 (n = 73)

-0.2 kg (n = 74)

 

'significant'

ABC trial [31]*

191

RCT

+ 1.16 (n = 96)

 

-0.04, atenolol (n = 95)

p = .019

Ott [32]

126

RCT

+2.0 (n = 63)

 

+ 0.9, atenolol (n = 63)

NS

Torvik [33]

172

RCT

+ 0.04 ± 0.2 (n = 58)

-1.18 ± 0.29 (n = 57)

+0.21 ± 0.2, prazosin (n = 57)

p < .001 for

treated groups

TOMHS [34]

902

RCT

-3.1 (n = 134)

 

-3.9, chlorthalidone (n = 136)

NS

  1. Comparison made by intention to treat; patients on doxazosin withdrawing from the ABC study (n = 39) had a mean weight gain of 2.21 kg. Trial included diet therapy for weight loss. p for comparison between groups and not from baseline.